Article thumbnail
Location of Repository

Immunization with a Chimera Consisting of the B Subunit of Shiga Toxin Type 2 and Brucella Lumazine Synthase Confers Total Protection against Shiga Toxins in Mice.

By Maria Pilar Mejias, Giselle Ghersi, Patricio Oliver Craig, Cecilia Analia Panek, Leticia Veronica Bentancor, Ariela Baschkier, Fernando Alberto Goldbaum, Vanesa Zylberman and Marina Sandra Palermo

Abstract

The striking feature of enterohemorrhagic Escherichia coli (EHEC) infections is the production of Shiga toxins (Stx) implicated in the development of the life-threatening hemolytic uremic syndrome. Despite the magnitude of the social impact of EHEC infections, no licensed vaccine or effective therapy is available for human use. One of the biggest challenges is to develop an effective and safe immunogen to ensure nontoxicity, as well as a strong input to the immune system to induce long-lasting, high-affinity Abs with anti-Stx–neutralizing capacity. The enzyme lumazine synthase from Brucella spp. (BLS) is a highly stable dimer of pentamers and a scaffold with enormous plasticity on which to display foreign Ags. Taking into account the advantages of BLS and the potential capacity of the B subunit of Stx2 to induce Abs that prevent Stx2 toxicity by blocking its entrance into the host cells, we engineered a new immunogen by inserting the B subunit of Stx2 at the amino termini of BLS. The resulting chimera demonstrated a strong capacity to induce a long-lasting humoral immune response in mice. The chimera induced Abs with high neutralizing capacity for Stx2 and its variants. Moreover, immunized mice were completely protected against i.v. Stx2 challenge, and weaned mice receiving an oral challenge with EHEC were completely protected by the transference of immune sera. We conclude that this novel immunogen represents a promising candidate for vaccine or Ab development with preventive or therapeutic ends, for use in hemolytic uremic syndrome–endemic areas or during future outbreaks caused by pathogenic strains of Stx-producing E. coli.Fil: Mejias, Maria Pilar. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental; ArgentinaFil: Ghersi, Giselle. Inmunova S.a; ArgentinaFil: Craig, Patricio Oliver. Fundación Instituto Leloir; ArgentinaFil: Panek, Cecilia Analia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental; ArgentinaFil: Bentancor, Leticia Veronica. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental; ArgentinaFil: Baschkier, Ariela. Dirección Nacional de Institutos de Investigación. Administración Nacional de Laboratorios e Institutos de Salud. Instituto Nacional de Enfermedades Infecciosas; ArgentinaFil: Goldbaum, Fernando Alberto. Inmunova S.a; Argentina. Fundación Instituto Leloir; ArgentinaFil: Zylberman, Vanesa. Inmunova S.a; Argentina. Fundación Instituto Leloir; ArgentinaFil: Palermo, Marina Sandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental; Argentin

Topics: Hemolytic Uremic Syndrome, SHIGA TOXIN 2, ANTI-STX2 ANTIBODIES, VACCINE, Biología Celular, Microbiología, Ciencias Biológicas, CIENCIAS NATURALES Y EXACTAS
Publisher: Amer Assoc Immunologists
Year: 2013
OAI identifier: oai:ri.conicet.gov.ar:11336/7774
Provided by: CONICET Digital
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/11336/77... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.